Administration information Recommended dosage : Single subcutaneous injection (6 mg) per chemotherapy cycle Not to be administered between 14 days before and 24 hours after administration of cytotoxic chemotherapy The prescribing information includes a warning for the following adverse reactions Splenic rupture Acute respiratory distress syndrome Use in patients with Sickle cell disease Glomerulonephritis Leukocytosis Thrombocytopenia Capillary leak syndrome Potential for growth stimulating effect on malignant cells Myelodysplastic syndrome Acute myeloid leukemia Aortitis Most common adverse reactions: bone pain and pain in extremities Additional adverse reactions (found in postmarketing surveillance) Alveolar hemorrhage Injection site reactions Sweet’s syndrome/acute febrile neutrophilic dermatosis Cutaneous vasculitis The association between drug use during pregnancy and the risk of…